Experimental diabetes drug trial halted early – what happened?

NCT ID NCT06611930

Terminated Disease control Sponsor: Cytoki Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called CK-0045 in 90 adults with type 2 diabetes and overweight or obesity. Participants received weekly injections of CK-0045 or a placebo for 16 weeks to see if it improved blood sugar after meals and reduced body weight. The trial was terminated early, so its effectiveness remains unknown.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CK-0045 (a lab-made protein that mimics interleukin-22)
What this could lead to: If it had worked, CK-0045 could have offered a new weekly injection to help control blood sugar and reduce weight in people with type 2 diabetes and obesity.
What could go wrong: The trial was terminated early, so results are not available. It was a small, early-phase study, and many such drugs fail to show benefit or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND OVERWEIGHT TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

CRS Clinical Reserach Services Mannheim GmbH

Mannheim, Baden-Wurttemberg, 68167, Germany
Profil Institut für Stoffwechselforschung GmbH

Neuss, D-41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.